Baiyunshan Pharmaceutical gains approval for atorvastatin calcium

Guangzhou Baiyunshan Pharmaceutical Holdings (SSE:600332) announced that its Baiyunshan Chemical Pharmaceutical Factory subsidiary has received an approval notice from the National Medical Products Administration for its atorvastatin calcium chemical raw material. The approved drug, indicated for hypercholesterolemia and cardiovascular disease prevention, comes in various packaging sizes, from 1Kg to 25Kg. According to SINOPHARM data, atorvastatin calcium tablets recorded sales of RMB 637.47 million in China’s public hospitals and pharmacies in 2023. The company believes this approval will broaden its cardiovascular product range and boost market competitiveness, but cautions investors about potential uncertainties due to policy and market factors.